Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

Sameer Bansilal, Zachary Bloomgarden, Jonathan L. Halperin, Anne S. Hellkamp, Yuliya Lokhnygina, Manesh R. Patel, Richard C. Becker, Günter Breithardt, Werner Hacke, Graeme J. Hankey, Christopher C. Nessel, Daniel E. Singer, Scott D. Berkowitz, Jonathan P. Piccini, Kenneth W. Mahaffey, Keith A.A. Fox

Research output: Contribution to journalArticlepeer-review

132 Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)'. Together they form a unique fingerprint.

Medicine & Life Sciences